Evaluation of the effects of N-Acetyl cysteine on sperm parameters,chromatin and genes expression in the terato-astenozoospermic men.

Evaluation of the effects of N-Acetyl cysteine on sperm parameters, biochemical-hormonal factors,c hromatin integrity and NRF2 ,HSPA2genes expression in the terato-astenozoospermic men.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170830035998N4

Enrollment

Registered

2018-03-14

Start date

2018-02-13

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Terato-Asethenozospermia. Male infertility

Interventions

Intervention 1: Intervention group or NAC group:received three tablets of NAC(200 mg daily) for three months. Intervention 2: Control group:before received three tablets of NAC(200 mg ).

Eligibility

Sex/Gender

Male

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Entry criteria: normal anatomy of the genital area; infertility due to teratology - asthenospermia wHO2010 criteria

Exclusion criteria

Exclusion criteria: Exclusion Criteria: Genital infection during the study; systemic medication for other infections; intake of dietary supplements 3 months before study; positive history of contact with chemical substances, solvents and inorganic substances; specimens from subjects with known etiology (varicocele, cryptorchidism, urinary tract infection, trauma, chemotherapy and etc.); individuals younger than 20 years or older than 40 years old; Individuals with varicocele; prostatitis; epidimitis; orchidism; mumps; testicular trauma; hyperthyroidism; hypothyroisdism; diabetes; thalassemia major; genetic disorders affecting infertility (Klinefelter , Noonan syndrome , microdeletion of chromosome Y, the mitochondrial DNA mutations); histotry of hernia surgery; vasectomy; consumption of antioxidant drugs

Design outcomes

Primary

Measure	Time frame
Sperm morphology. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;Sperm motility. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;Sperm concentration. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;DNA fragmentation. Timepoint: before and after taking drug. Method of measurement: Fluorescent microscope.;Protamine deficiency. Timepoint: before and after taking drug. Method of measurement: Fluorescent microscope.;Antioxidant enzymes. Timepoint: before and after taking drug. Method of measurement: spetophotometery.;Gene expression. Timepoint: before and after taking drug. Method of measurement: RT- PCR.	—

Measure

Time frame

Sperm morphology. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;Sperm motility. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;Sperm concentration. Timepoint: before and after taking drug. Method of measurement: Optical microscope, based WHO criteria (2010).;DNA fragmentation. Timepoint: before and after taking drug. Method of measurement: Fluorescent microscope.;Protamine deficiency. Timepoint: before and after taking drug. Method of measurement: Fluorescent microscope.;Antioxidant enzymes. Timepoint: before and after taking drug. Method of measurement: spetophotometery.;Gene expression. Timepoint: before and after taking drug. Method of measurement: RT- PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Rahil Janatifar

Infertility Center of Qom

janatifar@acecr.ac.ir+98 25 3270 0155

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026